Holen Sie sich die Stockscreener-App
211.96
2.79%
-6.08
Vorhandelsmarkt:
210.90
-1.06
-0.50%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$218.04
Offen:
$216.68
24-Stunden-Volumen:
8.87M
Relative Volume:
1.65
Marktkapitalisierung:
$374.44B
Einnahmen:
$59.64B
Nettoeinkommen (Verlust:
$2.37B
KGV:
159.25
EPS:
1.331
Netto-Cashflow:
$18.24B
1W Leistung:
-7.05%
1M Leistung:
-9.38%
6M Leistung:
+6.80%
1J Leistung:
+4.13%
1-Tages-Spanne:
$211.69
$219.00
1-Wochen-Bereich:
$211.69
$229.65
52-Wochen-Spanne:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
211.96 | 385.18B | 59.64B | 2.37B | 18.24B | 1.331 |
|
LLY
Lilly Eli Co
|
896.53 | 772.28B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.26 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
123.86 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
82.49 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
EPG Wealth Management LLC Sells 2,439 Shares of AbbVie Inc. $ABBV - MarketBeat
2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon - The Motley Fool
Colorado Judge Denies AbbVie's Bid To Block State Drug Law - Law360
Citigroup Lowers Price Target for AbbVie (ABBV) to $235 Amidst N - GuruFocus
AbbVie, Novartis Win Block of Oklahoma Drug Discount Law - Bloomberg Law News
The AbbVie Decision and the Economics of Corporate Control Markets - The National Law Review
Do Wall Street Analysts Like AbbVie Stock? - Barchart.com
JP Morgan Raises Price Target on AbbVie (ABBV) to $260, Maintains Overweight Rating | ABBV Stock News - GuruFocus
ABBV Q3 Deep Dive: Immunology Growth and Pipeline Expansion Offset Margin Pressure - TradingView
Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio - Insider Monkey
Goldman Sachs Adjusts Price Target on AbbVie to $223 From $218 - MarketScreener
Analyst on AbbVie (ABBV): ‘Stay Long’ - Insider Monkey
Obermeyer Wealth Partners Sells 12,006 Shares of AbbVie Inc. $ABBV - MarketBeat
Bank of New York Mellon Corp Cuts Position in AbbVie Inc. $ABBV - MarketBeat
Street View: Immunology strength holds at AbbVie despite aesthetics drag - TradingView
AbbVie Inc. $ABBV Shares Acquired by Machina Capital S.A.S. - MarketBeat
AbbVie Inc. $ABBV Holdings Lifted by Tsfg LLC - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Bank of Montreal Can - MarketBeat
Raymond James raises Abbvie stock price target to $256 on solid growth - Investing.com Nigeria
AbbVie Inc. $ABBV Shares Sold by Texas Bank & Trust Co - MarketBeat
Torray Investment Partners LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Raymond James Adjusts Price Target on AbbVie to $256 From $250, Maintains Outperform Rating - MarketScreener
JPMorgan Adjusts Price Target on AbbVie to $260 From $250, Maintains Overweight Rating - MarketScreener
BNP Paribas Exane Adjusts Price Target on AbbVie to $203 From $197, Maintains Neutral Rating - MarketScreener
Burney Co. Has $11.59 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. stock undervalued at current priceGap Up & High Accuracy Investment Entry Signals - newser.com
Sigma Planning Corp Sells 4,396 Shares of AbbVie Inc. $ABBV - MarketBeat
United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key PlayersNovartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb - GlobeNewswire
Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 2025Market Risk Analysis & High Return Stock Watch Alerts - newser.com
Targeted Drug Delivery Market Set to Witness Massive Growth - openPR.com
Will AbbVie Inc. stock attract more institutional investorsJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Will AbbVie Inc. stock beat EPS estimatesProduct Launch & Real-Time Stock Movement Alerts - newser.com
Why AbbVie Inc. (4AB) stock stays on top picks2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
How to recover losses in AbbVie Inc. stockWeekly Profit Analysis & Stock Portfolio Risk Management - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionWeekly Stock Summary & Capital Efficient Trading Techniques - newser.com
Reversal indicators forming on AbbVie Inc. stockEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Can AbbVie Inc. stock retain market dominance2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
State of Michigan Retirement System Buys 1,400 Shares of AbbVie Inc. $ABBV - MarketBeat
Nicholas Company Inc. Cuts Holdings in AbbVie Inc. $ABBV - MarketBeat
Tredje AP fonden Cuts Position in AbbVie Inc. $ABBV - MarketBeat
Triglav Investments D.O.O. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
SS&H Financial Advisors Inc. Buys 8,330 Shares of AbbVie Inc. $ABBV - MarketBeat
TIAA Trust National Association Sells 10,325 Shares of AbbVie Inc. $ABBV - MarketBeat
Accuvest Global Advisors Sells 1,690 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Great Lakes Retirement Inc. - MarketBeat
Why AbbVie Stock Flopped on Friday - AOL.com
AbbVie (ABBV) Surpasses Q3 Expectations with Strong Revenue Grow - GuruFocus
Earnings Scorecard: 24 out of 25 healthcare firms deliver EPS wins this week - Seeking Alpha
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat - MSN
AbbVie (ABBV) Reports $14.5 Billion One-Off Loss, Undercutting Bullish Margin Recovery Narratives - Sahm
Longbow Finance SA Purchases 37,626 Shares of AbbVie Inc. $ABBV - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):